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ABSTRACT AMPA-type glutamate receptors are tetrameric ion channels that mediate fast excitatory synaptic transmission in
the mammalian brain. When agonists occupy the binding domain of individual receptor subunits, this domain closes, triggering
rearrangements that couple agonist binding to channel opening. Here we compare the kinetic behavior of GluR2 channels
activated by four different ligands, glutamate, AMPA, quisqualate, and 2-Me-Tet-AMPA, full agonists that vary in potency by up
to two orders of magnitude. After reduction of desensitization with cyclothiazide, deactivation decays were strongly agonist
dependent. The time constants of decay increased with potency, and slow components in the multiexponential decays became
more prominent. The desensitization decays of agonist-activated currents also contained multiple exponential components, but
they were similar for the four agonists. The time course of recovery from desensitization produced by each agonist was
described by two sigmoid components, and the speed of recovery varied substantially. Recovery was fastest for glutamate and
slowest for 2-Me-Tet-AMPA, and the amplitude of the slow component of recovery increased with agonist potency. The multiple
kinetic components appear to arise from closed-state transitions that precede channel gating. Stargazin increases the slow
kinetic components, and they likely contribute to the biexponential decay of excitatory postsynaptic currents.
INTRODUCTION
Glutamate is the main excitatory transmitter in the mammalian
brain, and members of three subfamilies of glutamate recep-
tors (GluRs), 2-amino-3-(3-hydroxy-5-methyl-4-isoxazole)
propionic acid (AMPA), kainate, and N-methyl-D-aspartate
(NMDA), are ligand-gated ion channels that are found at
synapses throughout the central nervous system (1,2). Struc-
tures of the isolated ligand-binding core from the AMPA
receptor (AMPAR) subunit GluR2 (GluR2-S1S2) show that
glutamate and other agonists bind at the base of a deep cleft
between two globular domains (1 and 2), causing the trans-
lation and rotation of domain 2 such that the cleft closes
(3–5). Comparison of the structure of GluR2-S1S2 in com-
plex with various ligands has shown that the ligand-binding
core can adopt multiple agonist-dependent conformations
and that differences in agonist efﬁcacy correlate with dif-
ferent amounts of cleft closure (5–7).
The closed-cleft conformation is stabilized by interactions
between ligands and residues in domains 1 and 2 as well as
by direct and water-mediated hydrogen bonds that occur
only after the binding cleft closes. The relationship between
the extent of cleft closure and channel function has been the
focus of several studies, but much less is known about how
the stability of the closed-cleft conformation impacts channel
properties. Early GluR2-S1S2 crystal structures indicate that
binding domain closure renders the entire binding cleft in-
accessible to solvent, likely trapping agonists in the cleft (3).
This raised the possibility that the rate at which agonists
dissociate, a major determinant of receptor afﬁnity, may pri-
marily be determined by the rate at which the binding do-
main opens (3,8). Consistent with this view, binding cleft
mutations predicted to destabilize the closed-cleft confor-
mation increased the apparent rate of agonist dissociation
and also altered the relative efﬁcacies of glutamate and
quisqualate (9).
To explore further the relationships among agonist pot-
ency, the stability of the closed binding cleft, and AMPAR
function, we have characterized the kinetic behavior of
GluR2 channels when activated by glutamate, AMPA,
quisqualate, or (S)-2-amino-3-[3-hydroxy-5-(2-methyl-2H-
5-tetrazolyl)-4-isoxazolyl]propionic acid (2-Me-Tet-AMPA
(10,11)). These four ligands differ substantially in potency
but are all full agonists at wild-type AMPARs and produce
similar amounts of binding domain closure (3,8,12). The
results reveal kinetic behavior that may reﬂect differences in
the stability of the closed-cleft conformation, which we sug-
gest could contribute to the kinetics of excitatory postsyn-
aptic currents (EPSCs).
METHODS
The tsA201 cells were maintained and transfected as described (13). The
GluR2 plasmid used in this study was the ﬂip splice variant and encoded a
glutamine at the Q/R site (kindly provided by Mark Mayer, NIH). The
stargazin plasmid was a generous gift from Susumu Tomita (UCSF). GluR4
and stargazin plasmids were cotransfected at a 1:2 ratio. Recordings from
outside-out patches were performed 24 to 48 h posttransfection at room
temperature (14). The holding potential was 80 mV, and series resistance
compensation was set at 60–80%. The external solution was (in mM): 150
Submitted March 6, 2006, and accepted for publication May 17, 2006.
Wei Zhang and Antoine Robert contributed equally to this work.
Address reprint requests to James R. Howe, Dept. of Pharmacology,
Yale University, SHM B-251, 333 Cedar St., New Haven, CT 06520-8066.
Tel.: 203-737-2398; Fax: 203-785-7670; E-mail: james.howe@yale.edu.
 2006 by the Biophysical Society
0006-3495/06/08/1336/11 $2.00 doi: 10.1529/biophysj.106.084426
1336 Biophysical Journal Volume 91 August 2006 1336–1346
NaCl, 3 KCl, 2 CaCl2, 1 MgCl2, 5 glucose, 10 HEPES, pH 7.4. Patch
pipettes (open tip resistance 3 to 5 MV) were ﬁlled with a solution
containing (in mM): 135 CsF, 33 CsOH, 2 MgCl2, 1 CaCl2, 11 EGTA,
10 HEPES, pH 7.4. Glutamate, AMPA, quisqualate, 2-Me-Tet-AMPA, and
cyclothiazide were added to the external solution and applied with u-pipettes
mounted on a piezoelectric bimorph (13,14). At the end of some recordings,
junction currents evoked by changes in open-tip potentials were measured.
The 10–90% risetimes of these currents gave solution exchange times of
100–200 ms. At high agonist concentrations, the 10–90% risetimes of
agonist-evoked currents were typically 400–500 ms.
Agonist-evoked currents were analog low-pass ﬁltered at 3 kHz, sampled
at 20–50 kHz, and written directly to the hard drive of the computer. For
deactivation and the onset of desensitization, 20 to 30 consecutive responses
were averaged, and exponential functions were ﬁtted to the decays of the
mean currents with Igor software (Wavemetrics, Lake Oswego, OR). The
number of exponential components required was determined from inspec-
tion of the residual traces and nested t-tests (15) as described in detail before
(14). Concentration–response data were normalized (see Results), and the
mean normalized results were ﬁtted with Hill-type functions to obtain EC50
values and values for the Hill coefﬁcient. Recovery data were obtained from
two-pulse protocols. The peak amplitude of the current evoked by the
second pulse was expressed as a fraction of the response to the paired ﬁrst
pulse. Mean results from several patches were ﬁtted with the equation:
It ¼ I01 Ia½1 expðt=taÞma
1 ð1 Ia  I0Þ½1 expðt=tbÞmb ;
where It is the peak current at a given interpulse interval t, Ia and Ib are the
limiting amplitudes of the fast and slow components of recovery, I0 is the
current at zero time (the relative amplitude of the plateau current at the end
of the ﬁrst pulse), and ta,tb and ma,mb are the respective time constants
and exponents of each component of recovery.
Monte Carlo simulations and kinetic modeling were done with Channel
Lab software (Synaptosoft, Decatur, GA). Details of the procedures have
been published previously (9,13,16) and are given in the Supplementary
Material.
RESULTS
Crystallographic structures of GluR2-S1S2 and the kinetics
of glutamate binding to the isolated AMPAR binding core
suggest that the rate at which the binding cleft opens may be
a major determinant of agonist afﬁnity (3,8,12,17). For glu-
tamate and quisqualate, recent patch-clamp studies of wild-
type and mutant GluR2 channels suggested that the stability
of the closed-cleft conformation can also inﬂuence the efﬁ-
cacy of agonists (9). Here we compare the kinetic properties
of GluR2 channels activated by four agonists that display
large differences in potency (and likely different stabilities
of the closed-cleft conformation).
Agonist potency and the kinetics of deactivation
Fig. 1 a shows concentration–response curves for glutamate,
AMPA, quisqualate, and 2-Me-Tet-AMPA that were ob-
tained by measuring steady-state currents after reduction of
desensitization with 100 mM cyclothiazide (CTZ). Currents
from individual outside-out patches were normalized to
the size of the current evoked in the same patch by a
FIGURE 1 Deactivation shows agonist-dependent components that do not depend on receptor occupancy. (a) Mean concentration–response data for steady-
state currents (in 100 mM CTZ). The smooth curves are Hill-type ﬁts. Current amplitudes were normalized to currents evoked in the same patch by near-
saturating concentrations. Error bars show mean 6 SE values, which in most cases were less than half the symbol size. (b) Currents evoked in individual
patches by 2-ms applications (arrowheads) of 10 mM glutamate, 0.5 mMAMPA, 0.2 mM quisqualate, and 0.1 mM 2-Me-Tet-AMPA (in CTZ). The decays of
the currents were ﬁtted with multiexponential functions (solid curves; individual components shown as dashed lines). (c) For each of the four agonists,
weighted mean time constants are plotted against the EC50 ratio (glutamate EC50/agonist EC50). (d) Currents evoked by different concentrations of 2-Me-
Tet-AMPA (left). In the panels to the right, the individual currents were scaled to have the same peak amplitude, and the slow components obtained from
the biexponential ﬁts to the decays are shown as solid curves.
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near-saturating concentration of agonist. Hill-type ﬁts to the
mean results gave EC50 values of 296 mM, 66.2 mM, 16.3
mM, and 3.4 mM for glutamate, AMPA, quisqualate, and 2-
Me-Tet-AMPA, respectively (Hill coefﬁcients: 1.09–1.34).
Although the EC50 values are larger by about three orders of
magnitude than the equilibrium dissociation constants esti-
mated for binding of each agonist to the isolated GluR2
binding core, the relative differences in agonist potency
agree well with the corresponding differences in afﬁnity
determined in binding experiments (Table 1).
To determine how differences in potency correlated with
the rate of deactivation, we next compared the time course
with which the currents decayed on termination of 2-ms
applications of each agonist (in CTZ). Representative results
are shown in Fig. 1 b. The deactivation decays were ﬁtted
adequately with two exponential components for glutamate,
AMPA, and quisqualate, but three exponential components
were consistently observed in the decays of currents evoked
by 2-Me-Tet-AMPA. The mean time constants and relative
amplitudes obtained from multiexponential ﬁts to the deac-
tivation decays are given in Table 1.
The deactivation decays were strongly agonist dependent,
being fastest for glutamate and slowest for 2-Me-Tet-AMPA.
The timeconstants for thecorrespondingcomponents increased
with agonist potency, and the slow components of decay be-
came increasingly prominent. Although the fast component
of decay dominated the time course seen with glutamate
(99.1%), the relative amplitude of the fast component was only
19%with2-Me-Tet-AMPA.As an indexof the overall speedof
deactivation, mean time constants were calculated for each
patch, where the time constants of each component obtained
from the multiexponential ﬁts were weighted by their relative
amplitudes. In Fig. 1 c, the weighted mean time constants for
each agonist are plotted against the corresponding fold differ-
ences in potency. The correlation between these two param-
eters was excellent (p, 0.001; linear regression analysis).
AMPARs are tetrameric assemblies in which each of the
four subunits contains a binding site for glutamate, and indi-
vidual AMPARs open to increasingly large conductance
levels as the number of subunits occupied by agonist in-
creases (18,19). At the concentrations used in the deactiva-
tion protocols illustrated in Fig. 1 b, most receptors are likely
fully occupied at the end of the application, and multiple
agonist molecules must dissociate before the channel is no
longer able to open. The probability that channels will open
after free agonist is removed will increase as the rate of
dissociation slows, and if partially occupied channels have
different gating kinetics, this might give rise to multiexpo-
nential decays. To test this possibility, we compared the
deactivation kinetics at agonist concentrations that gave
substantially different steady-state currents. As illustrated for
2-Me-Tet-AMPA in Fig. 1 d, for each of the agonists, deac-
tivation decays did not vary signiﬁcantly with concentration.
These results argue against the idea that the multiple de-
activation components detected with each agonist reﬂect
occupancy-dependent differences in the kinetics of gating.
Desensitization is biexponential
We next examined the kinetics of the channels with desen-
sitization intact. We noted previously that the desensitization
decays of glutamate-activated currents through GluR1 and
GluR4 homomeric channels were biexponential (14,20). The
desensitization decays of GluR2-mediated currents were
likewise consistently biexponential. This is illustrated in
Fig. 2 a, where the decay of a typical current elicited by a
sustained application of 10 mM glutamate has been ﬁtted
with one or two exponential components. Although single
exponential ﬁts were not obviously poor, the ﬁts deviated
systematically during the early and late phases of decay, as
evidenced by inspection of the residual trace (the point-by-
point difference between the data and the ﬁt). In contrast,
biexponential ﬁts gave ﬂat residual traces and were signif-
icantly better as assessed by nested t-tests for currents evoked
in each of nine patches (p , 0.01 (15)). Similar results were
obtained for currents activated by lower concentrations of
glutamate (Fig. 2 b), and comparison of the mean results for
500 mM and 10 or 20 mM glutamate demonstrated that the
TABLE 1 Properties of GluR2 currents evoked by the four agonists
Deactivation* Desensitizationy Recoveryz
t1 (ms) t2 (ms) t3 (ms)
Fast
component
(%) tf (ms) ts (ms)
Slow
component
(%)
ta
(ms)
tb
(ms) ma mb
Slow
component
(%) EC50 (mM) KD
§ (nM)
Glu 1.3 6 0.2 17 6 3.5 99 6 0.5 4.6 6 0.5 15 6 2.1 14 6 2.3 17 82 2.3 2.0 13 296 6 19.2 89–460 (3,46,47)
AMPA 6.3 6 0.5 27 6 4.2 78 6 6.6 3.8 6 0.4 11 6 1.0 24 6 2.4 130 582 1.4 1.1 32 66.2 6 2.3 11–25 (3,12,46,47)
Quis 8.5 6 0.6 32 6 4.7 73 6 5.3 3.7 6 0.3 15 6 3.2 10 6 3.8 99 460 1.8 1.4 37 16.3 6 0.5 7.6–12 (12,46)
2-Me-Tet-
AMPA
9.1 6 1.4 54 6 2.7 156 6 8.4 19 6 5.0 8.4 6 0.9 46 6 7.0 9.0 6 4.0 824 3474 1.6 1.5 58 3.4 6 0.8 3.8 (8)
*Mean (6 SE) values from multiexponential ﬁts to the current decays during 2-ms applications of agonist in 100 mM CTZ (n ¼ 4 to 6 patches per agonist).
yMean (6 SE) values from biexponential ﬁts to the current decays during 100-ms applications of agonist (n ¼ 4 to 9 patches per agonist).
zValues from double Hodgkin-Huxley-like ﬁts to the mean data shown in Fig. 6 (n ¼ 6 to 8 patches per agonist).
§Values for binding to GluR2-S1S2 (from indicated references). When IC50 values were measured, we converted them to KD values with the equation: KDI ¼
IC50/(1 1 [L]/KDL), where KDI is the KD of the competing ligand, and [L] and KDL are the concentration of radioligand and its KD value.
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desensitization decays did not depend signiﬁcantly on recep-
tor occupancy.
The desensitization decays of currents elicited by AMPA,
quisqualate, and 2-Me-Tet-AMPA were also consistently
ﬁtted better by two exponential components (as assessed by
inspection of the residuals and nested t-tests). As for gluta-
mate, inclusion of a third component did not signiﬁcantly
improve the ﬁts. Examples of currents evoked by each of the
four agonists are shown in Fig. 3. In contrast to the deacti-
vation decays in CTZ, the time course of desensitization did
not correlate with agonist potency. The mean time constants
and relative amplitude of the slow component of decay are
given in Table 1. The mean (6 SD) steady-state currents
(expressed as a percentage of the peak current) were 2.1 6
0.4%, 1.4 6 0.2%, 0.9 6 0.1%, and 0.8 6 0.3% for
glutamate, AMPA, quisqualate, and 2-Me-Tet-AMPA, re-
spectively.
The results show that agonist potency does not signiﬁ-
cantly inﬂuence the rate of entry into desensitization or the
relative amplitudes of the fast and slow components. For
AMPA receptors, many published reports indicate that desen-
sitization and channel opening primarily occur in parallel
from the same closed states. As a result, time constants of
desensitization reﬂect the ratio of the rate constants for chan-
nel opening and entry into desensitization (b and d in Fig. 4),
which determine the average number of openings per chan-
nel before they desensitize, as well as the rate constant for
channel closing, a, the reciprocal of which determines the
duration of each opening. The simplest explanation for the
similar desensitization time constants obtained with each
agonist is that these three rate constants are similar for all
four agonists. The similar amplitudes of the slow compo-
nents of desensitization seen with each agonist also suggest
that the states that give rise to the multiple deactivation
components in CTZ are populated slowly relative to de-
sensitization.
GluR2 kinetics can be modeled by sequential,
but not parallel, conformational changes
To gain insight into the source of the kinetic behavior de-
scribed above, we performed Monte Carlo simulations of
agonist-evoked currents. Previous kinetic mechanisms we
proposed accounted for the tetrameric structure of AMPA
receptors, with each subunit providing a binding site for
agonists (9,13,16). Our kinetic models also included multiple
desensitization transitions to account for the two-step nature
of recovery from desensitization, which likely reﬂects the
dimer-of-dimers organization of the channels (13,21). How-
ever, the results reported here were obtained at near-
saturating concentrations, and the kinetics of the current
decays did not depend signiﬁcantly on receptor occupancy
FIGURE 2 Glutamate-induced desensitization shows multiple kinetic
components that do not depend on receptor occupancy. (a) Current evoked
by 100-ms applications of 10 mM glutamate. Left and right panels show
one- and two-exponential ﬁts (solid curves) to the decays. The residuals are
also shown (res; obtained by subtracting the data from the ﬁt). Insets are the
same currents and ﬁts on an expanded timescale (dashed lines show
individual components). (b) Currents evoked by sustained applications of
two different concentrations of glutamate (left). In the panels to the right, the
individual currents were scaled to have the same peak amplitude. The
individual components obtained from the biexponential ﬁts to the decays are
shown as dashed curves.
FIGURE 3 Desensitization decays are similar for each agonist. Currents
evoked by 100-ms applications of (a) 10 mM glutamate, (b) 0.5 mMAMPA,
(c) 0.2 mM quisqualate, and (d) 0.1 mM 2-Me-Tet-AMPA. The decays of
the currents were ﬁtted with biexponential functions (solid curves; dashed
lines show individual components).
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(Figs. 1 d and 2 b). In addition, our previous work showed
that occupancy of a single subunit was sufﬁcient to desen-
sitize GluR1 and GluR4 channels (13). Therefore the mul-
tiple kinetic components described above likely reﬂect
channel behavior that is independent of the number of sub-
units contributing to the currents. We therefore treated the
receptor as though it were a single subunit, which greatly
simpliﬁed the modeling and is unlikely to substantially
impact the general conclusions. Open and closed transitions
in our simpliﬁed models would result in steps between
adjacent conductance levels in tetrameric channels.
The models we examined are shown in Fig. 4. Each model
contains three types of transitions (governed by the rate
constants in parentheses): a), transitions that correspond to
association and dissociation of agonist to the open-cleft
conformation of the binding domain (k11, k1); b), transi-
tions that correspond to closing and opening of the binding
domain or stabilization and destabilization of closed-cleft
conformations (CC, CO and CS, CD, respectively); and c),
gating transitions that correspond to conformational changes
that would lead to step changes in unitary conductance (b, a)
or desensitization and recovery from it (d, g). The multiple
open states in Fig. 4 have identical occupancies and unitary
conductances and do not correspond to the multiple open
states in our previous articles (9,13).
In model 1, we assumed that the multiple deactivation and
desensitization components arise from different kinetics of
activation gating. Once the binding cleft closes, the channel
can enter three kinetically distinct open states that have
different opening and closing rate constants. In model 2, we
assumed that the binding cleft could adopt one of three
closed-cleft conformations and that the rate constants gov-
erning these and subsequent gating steps differed. In model 3,
activation gating and desensitization occur from each of
three different closed-cleft conformations that are adopted
sequentially. Here the multiple components arise from the
kinetics of transitions between the closed states, not from the
kinetics of the open states (which are identical).
Models 1 and 2 invariably reproduced the experimental
results poorly. For example, b/a and CC/CO, CS/CD values
that reproduced the multiple deactivation components gave
activation time courses that were slower than those observed
and peak current amplitudes that depended on the duration of
exposure to agonist. In addition, the desensitization decays
could be reproduced only by setting the rate constant for
entry into desensitization (d) to values substantially larger
than b, which gave low peak popen values and steady-state
currents that were too small. In contrast, activation, deacti-
vation, and desensitization were all reproduced well by
model 3 (see Supplementary Material for details).
The speed of deactivation depends on the
duration of exposure to agonist
In model 3, the second and third cleft-closure steps equil-
ibrate slowly (CS and CD b and d). The values of CC, b,
a, and d are assumed to be identical or similar for each
agonist, ensuring rapid activation and similar desensitization
decays (supplemental Table 2, Supplementary Material), and
in the absence of CTZ, most channels will desensitize before
they reach the RG*2 and RG*3 states. A main feature of
model 3 is that the rate constant for binding cleft opening,
CO, and the steady-state occupancies of the RG* states differ
for the different agonists. With glutamate, most channels
reside in state RG*1, whereas with 2-Me-Tet-AMPA, the
channels are primarily in states RG*2 and RG*3. For the de-
activation protocols in CTZ, the slow components arise be-
cause channels in RG*3 and RG*2 must pass through states
RG*2 and RG*1 before the binding cleft can open. Gating
will continue during these sojourns, and the duration of this
activity will depend on how quickly the channels return to
state RG.
Because model 3 assumes that sequential occupancy of the
states RG*2 and RG*3 occurs slowly, the model predicts that
the speed of deactivation should depend on the duration of
the agonist applications. To test this prediction, we applied
each agonist for different times and analyzed the decays of
the currents at the end of the applications. Examples of the
results obtained with short and long applications are shown
in Fig. 5 a. For each agonist, and in all patches examined,
deactivation decays became slower as the length of the appli-
cation was increased, reﬂecting both an increase in the time
constants for the various decay components and an increase
in the relative amplitude of the slow components of decay.
As predicted from Monte Carlo simulations using model 3,
the weighted mean time constants of deactivation increased
as a function of application time. Plots of the weighted time
constants versus application duration were approximately ex-
ponential, and the time constants of exponential ﬁts to the
results increased with agonist potency (glutamate,AMPA,
quisqualate , 2-Me-Tet-AMPA). The experimental results
FIGURE 4 Possible kinetic mechanisms. In model 1, one cleft closure
step is followed by gating transitions to three different open states. In models
2 and 3, gating transitions are preceded by three cleft-closure steps that occur
in parallel or sequentially. Only a single subunit is shown.
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obtained with glutamate and 2-Me-Tet-AMPA are presented
in Fig. 5 b.
Recently we concluded that mutations at threonine 686 in
GluR2 speed the rate of glutamate dissociation by destabi-
lizing the closed-cleft conformation and increasing the rate at
which the binding cleft opens (9). If the deactivation time
course primarily reﬂects the stability of the closed-cleft
conformation, and the slow components arise from increas-
ingly stable closed-cleft conformations (as in model 3), then
the T686 mutations should decrease the deactivation time
constants and decrease the relative amplitude of the slow
decay components. We therefore compared the deactivation
decays seen with quisqualate for GluR2 and GluR2(T686S)
homomers. As shown in Fig. 5, c and d, the T686S mutation
increased the rate of deactivation and decreased the relative
amplitude of the slow component of decay.
Recovery from desensitization exhibits
multiple agonist-dependent components
With glutamate, AMPARs do not recover from desensitiz-
ation along a simple exponential time course, but rather, this
time course appears to be governed by two rate-determining
steps (13,21). We proposed that these steps correspond to
reassembly of the monomer–monomer interface in ﬁrst one
dimer and then the other, and that the rate at which the in-
terface reassembled was in part determined by the stability of
the closed conformation of the binding domain (9). With glu-
tamate, it has also been noted that a small proportion of the
channels recover much more slowly (13,22,23).
To investigate further the relationship between the
kinetics of recovery and agonist potency, we measured
recovery from desensitization for each agonist with stan-
dard two-pulse protocols. The left panels in Fig. 6, a–d,
show representative recovery results for glutamate, AMPA,
quisqualate, and 2-Me-Tet-AMPA (note different time-
scales). Mean data for each agonist from several patches are
presented in the middle panels, where the results have been
ﬁtted with the sum of two Hodgkin-Huxley–type compo-
nents (signiﬁcantly better than one-component ﬁts, p ,
0.01). The right panels show the data for AMPA and 2-Met-
Tet-AMPA on a faster timescale to illustrate the sigmoid
shape of the early phase of recovery.
In contrast to entry into desensitization, the time constants
of recovery and the relative amplitude of the slow component
became larger as agonist potency increased. The results sug-
gest that, as in deactivation, the recovery components equi-
librate slowly, and this equilibration continues after the
channels desensitize. Whether the fast and slow components
of deactivation and the fast and slow components of recovery
arise from a common mechanism is unclear. If this were true,
it might be expected that agonist-dependent differences in
the respective time constants and relative amplitudes would
be similar, which does not appear to be the case (Table 1).
For example, the difference in the recovery time constants
for 2-Met-Tet-AMPA and those for the other agonists is
much bigger than the corresponding differences for deacti-
vation. This discrepancy would be partially resolved, how-
ever, if we missed a small fast component of recovery
for 2-Met-Tet-AMPA and the two recovery components
FIGURE 5 Deactivation depends on the duration of exposure to agonist and is faster for T686S mutant channels. (a) Decays of currents at the end of 2-ms
(dotted traces) and 500-ms (solid traces) agonist applications (in CTZ). (b) Plot of weighted mean time constants of deactivation versus application time
(log scale) for glutamate and 2-Me-Tet-AMPA. The curves are single-exponential ﬁts. (c) Currents at the end of 50-ms applications of 0.2 mM quisqualate
for GluR2-WT (solid trace) and GluR2-T686S (dotted curve). (d) The time constants of deactivation were faster and the relative amplitude of the slow
component was smaller for the T686S mutant (mean 6 SE, four to six patches).
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detected correspond to gating modes that give rise to the
second and third components of deactivation.
The m values obtained from the recovery ﬁts varied for the
four agonists but were typically substantially greater than 1,
and for any given agonist, the m values were similar for the
two components. In total, the results suggest that both com-
ponents of recovery consist of two rate-determining transi-
tions and that the molecular determinants of the rate of
recovery are qualitatively similar for each recovery compo-
nent and for each agonist. We proposed previously that the
slow component of recovery detected for glutamate arose
from slow dissociation of the last bound glutamate from
desensitized channels (13). This proposal was never attrac-
tive from a structural standpoint, and our present results
suggest it is incorrect.
The effect of stargazin on AMPAR kinetics
For the GluR2 channels studied here, the slow components
detected in the decays of glutamate-activated currents are
small, likely too small to impact the shape of synaptic cur-
rents signiﬁcantly. However, native AMPARs interact with
various auxiliary proteins that localize the receptors at post-
synaptic densities. One such protein is stargazin, a member
of the transmembrane AMPAR regulatory protein (TARP)
family that was shown to be required for the localization of
AMPARs at mossy ﬁber/granule cell synapses in the cere-
bellum (24–27). In addition to its effects on receptor target-
ing, recent studies have shown that stargazin also alters
AMPAR gating, slowing both deactivation and desensitiz-
ation (20,28,29). Interactions between stargazin and GluRs
also increase the slow component of desensitization for
glutamate-activated currents and slow the decay of AMPAR
synaptic currents in neurons (20). The latter results suggest
that the multiple gating modes implicit in our results may
impact the shape of synaptic currents, especially if associ-
ation with stargazin increases the slow deactivation compo-
nent observed with glutamate.
To characterize further the effect of stargazin on the deac-
tivation kinetics of glutamate-activated AMPAR currents,
we compared the kinetics of these currents with and without
coexpression of stargazin. To compare the results with our
previous work (20), we chose GluR4 for these experiments.
In both the absence and presence of CTZ, coexpression of
stargazin signiﬁcantly slowed the deactivation time constants
and increased the relative amplitude of the slow deactivation
component seen with glutamate (Fig. 7). Thus, as shown
previously for desensitization (20), coexpression of stargazin
results in a signiﬁcant slow component in the decays of
currents evoked with glutamate. Because most native AMPA-
receptor complexes likely contain stargazin (or a related
TARP), the kinetic behavior that gives rise to the slow de-
activation and desensitization components may contribute to
the time course of the decay of EPSCs.
DISCUSSION
Our results demonstrate that AMPAR channels show kinetic
behavior that gives rise to multiple components in both de-
activation and desensitization decays. The multiple deacti-
vation components are most evident when desensitization is
reduced with CTZ and, under these conditions, the slow
FIGURE 6 Recovery from desensitization shows fast and slow components. Left panels are examples of the results from two-pulse protocols to measure
recovery from desensitization with 10 mM glutamate, 0.5 mM AMPA, 0.2 mM quisqualate, and 0.1 mM 2-Me-Tet-AMPA. Other panels show mean (6 SE)
data from six to eight patches. The data were ﬁtted with two Hodgkin-Huxley–type components. In b and d, the right panels show the early phase of recovery.
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deactivation components become larger as agonist potency
increases. The time constants of the individual components
likewise increase, and the overall speed of deactivation cor-
relates well with agonist potency. The similarity in the rates
of desensitization for the four agonists suggests that the
multiple components detected in CTZ arise from entry into
states that equilibrate slowly, a conclusion supported by the
dependence of the speed of deactivation on the duration of
exposure to agonist. Because activation and desensitization
occur largely in parallel (13,30–32), the similar desensitiz-
ation decays also suggest that the rate constants for channel
opening, closing, and entry into desensitization (b, a, and d
in Fig. 4) are similar for the four agonists, a conclusion
consistent with our Monte Carlo simulations (supplemental
Table 2, Supplementary Material).
Binding domain closure and agonist potency
As noted, substantial evidence indicates that agonist binding
to AMPA receptors is accompanied by closure of the binding
cleft between domains 1 and 2, and the extent to which the
binding cleft closes is a major determinant of agonist efﬁcacy
(3–7). The available evidence strongly suggests that binding
domain closure also leads to rearrangement of the dimer in-
terface that uncouples domain closure from activation and
results in desensitization (32). The similar rates at which the
four full agonists studied here desensitize, all of which result
in similar amounts of binding domain closure in GluR2-
S1S2 crystal structures (3,8,12), are consistent with these
previous conclusions.
Closure of the binding domain traps agonists in the cleft,
and the stability of the closed-cleft conformation therefore
substantially impacts the rate at which they dissociate and the
kinetics of deactivation (4,8,9). The results presented here
are consistent with model 3, where the multiple kinetic
components arise from closed-cleft conformations that differ
in stability and where increases in agonist potency correlate
with increased occupancy of more stable conformations.
Crystal structures of the GluR2-S1S2 binding core in com-
plex with each of the four agonists reveal differences in the
detailed interactions within the cleft that might be expected
to inﬂuence the stability of the closed-cleft conformation
(3,8,12). For example, there are signiﬁcant differences in the
interactions made by the substituents corresponding to the
g-carboxylate group of glutamate. The g-carboxyl oxygen of
glutamate interacts with the domain 2 residues S654 and
T655 in GluR2 and forms a water-mediated hydrogen bond
with the backbone amide of E705 (3). In the AMPA- and
quisqualate-bound structures, the water-mediated hydrogen
bond with E705 is replaced by direct ligand–protein hydro-
gen bonds formed with the AMPA isoxazole nitrogen and
the 5-carbonyl oxygen of quisqualate (3,12). As another ex-
ample, both AMPA and 2-Me-Tet-AMPA contain an iso-
xazole ring, but this shared moiety adopts different positions
within the binding cleft, resulting in two additional direct
ligand–protein interactions in the 2-Me-Tet-AMPA struc-
ture (3,8). In addition, the 2-methyltetrazole group of 2-Me-
Tet-AMPA ﬁlls a partially hydrophobic pocket formed by
several residues in domains 1 and 2 more completely than the
5-methyl group of AMPA, and these hydrophobic interac-
tions are absent for glutamate and quisqualate (3,8,12).
Key residues in the binding pocket also adopt different
conformations in the different agonist-bound GluR2-S1S2
structures. For example, the peptide bond between the do-
main 2 residues D651 and S652 assumes a cis orientation in
all AMPA and 2-Met-Tet-AMPA protomers (3,12). This
peptide bond ‘‘ﬂip,’’ which results in two additional hydro-
gen bonds with backbone atoms on residues in domain 1,
FIGURE 7 Stargazin increases the
slow component of deactivation. (a and
b) Currents evoked by 2-ms applications
of 10 mM glutamate (no CTZ) in patches
containing GluR4 (a) or GluR4 and
stargazin (b). The slow components from
biexponential ﬁts to the decays are shown
(solid curves). Peak currents are off-scale.
(c) Currents evoked by 2-ms applications
of 10 mM glutamate (in CTZ) in patches
containing GluR4 (dotted trace) and
GluR4/stargazin (solid trace) channels.
(d) Mean time constants for the fast and
slowdeactivation components (t1, t2: left
and middle panels) and the mean relative
amplitude of the slow component (right)
without and with coexpression of starga-
zin in the absence and presence of CTZ.
Stargazin increased both deactivation
time constants and the relative amplitude
of the slow deactivation component seen
with and without CTZ (mean6 SE, data
from four and six patches).
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was observed in four of ﬁve quisqualate-bound structures but
only one of three glutamate-bound protomers (3,12). There
are also differences in the rotamer orientations of the side
chains of L650 and M708 among the four agonists (3,8,12).
In total, the noted differences support the view that the
strength of interdomain interactions and the stability of bind-
ing cleft closure are positively correlated with agonist po-
tency, and, given the complexity of the interactions involved,
it seems reasonable that multiple agonist-bound conforma-
tions might be adopted that differ in relative frequency and
stability.
The contribution of closed-state transitions to
AMPAR kinetics
Our Monte Carlo simulations suggest that the multiple
components of deactivation, desensitization, and recovery
we describe here result primarily from a series of slowly
equilibrating closed states, not from differences in open-state
kinetics. In model 3, we assume that the sequential closed-
state transitions correspond to conformational changes within
the binding cleft, but we have no direct evidence for this, and
the RG*2 and RG*3 states may result from rearrangements
within other portions of the protein. We also have no evi-
dence that the putative multiple conformations are the same
for each agonist (as implied in model 3); this is merely a
simple explanation for our results. All model 3 requires is
that the binding cleft remains closed during transitions be-
tween the RG* states, preventing agonist dissociation and
allowing both activation gating and desensitization. Al-
though they need not be identical, it is also implicit in model
3 that the b and a values be similar for the different RG*
states (and the different agonists) because the different deac-
tivation and desensitization components arise not from large
differences in the kinetics of transitions governed by these
rate constants but from the kinetics of the sequential closed-
cleft transitions.
Although the detailed molecular interactions underlying
the multiple kinetic components remain to be resolved, one
clear result from our studies is that the multiple deactivation
components seen with each full agonist show a strong depen-
dence on agonist potency. The EC50 values measured in CTZ
are linearly correlated with the weighted time constants of
deactivation (Fig. 1 c), which reﬂect both increased time
constants and increased amplitudes of the slower compo-
nents as agonist potency increases. The relative potencies of
the four agonists also agree well with the relative KD values
obtained in binding experiments with the isolated GluR2-
S1S2 binding core (Table 1), consistent with the idea that the
multiple kinetic components seen in our experiments arise
from multiple conformations of the binding domain. It seems
likely that the large disparity between EC50 and KD values
for individual agonists in Table 1 results because domain 2 is
tethered to the ﬁrst and second transmembrane helices in the
intact channel, which may, in general, destabilize the closed-
cleft conformation. In binding experiments on full-length
receptors, KD values are strongly skewed by desensitization,
which results from rearrangement of the dimer interface (32)
and is accompanied by stabilization of the closed-cleft con-
formation of the binding domain (13). In binding experi-
ments, the similarity between the KD values for full-length
receptors and the corresponding values obtained with the
isolated binding core likely arises because in both cases the
strain imposed by the open state of the channel is relieved,
albeit for different reasons, resulting in increased stability
of the closed-cleft conformation.
The effect of stargazin
In addition to its effects on receptor trafﬁcking, recent reports
show that the auxiliary subunit stargazin inﬂuences AMPA
receptor gating (20,28,29). Single-channel studies demon-
strated that stargazin increases the relative frequency of large-
conductance openings and causes a twofold increase in the
duration of bursts (20). The increased burst durations reﬂect
an increased number of openings per burst without altera-
tions in the length of individual openings, showing that one
primary effect of stargazin is to increase the rate constant
for channel opening (b). The effects of stargazin to slow both
deactivation and desensitization decays are consistent with
the single-channel results.
The enhancement of the slow component detected with
glutamate in the deactivation decays suggests that stargazin
also promotes kinetic behavior seen with more potent ago-
nists, perhaps by shifting the equilibrium toward more stable
channel conformations in which the binding cleft remains
closed. Interestingly, the effects of stargazin on deactivation
decays were similar in the absence and presence of CTZ.
Thus, although both stargazin and CTZ slow deactivation,
they appear to do so via independent mechanisms.
The substantial slow component of deactivation seen with
glutamate after coexpression of stargazin strongly suggests
that the kinetic behavior described here contributes to the
shape of synaptic currents and therefore to the ﬁdelity of fre-
quency encoding at CNS synapses. Although the amplitudes
of the slow deactivation and desensitization components are
relatively small, with stargazin, the total charge transfer
during the fast and slow components is similar. Because
many AMPARs show appreciable calcium permeability, the
slow component may also contribute signiﬁcantly to calcium-
mediated signaling.
It is generally accepted that the kinetic behavior of NMDA
receptors inﬂuences synaptic signaling, and recent single-
channel studies of NMDA and glycine receptors indicate that
channel opening is preceded by slow conformational changes
similar to the closed-cleft transitions in model 3 (33,34). For
NMDA receptors, the kinetics of these pregating transitions
are such that they impact the size of responses to consecutive
glutamate applications and may play a role in short-term
changes in synaptic strength. Although many presynaptic
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and postsynaptic factors potentially inﬂuence the rapid
kinetics of AMPAR EPSCs (35), relatively little attention
has been focused on the contribution of the kinetic behavior
of the channels themselves. The biexponential decay of
AMPA-receptor EPSCs noted in many previous studies has
been suggested to result from heterogeneity in the postsyn-
aptic receptor population, the kinetics of glutamate release
and clearance, synapse geometry, or spillover from neighbor-
ing release sites (30,36–45). Our results indicate that the
intrinsic kinetic properties of AMPARs likely also contribute
to the biexponential decays of EPSCs.
SUPPLEMENTARY MATERIAL
An online supplement to this article can be found by visiting
BJ Online at http://www.biophysj.org.
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